Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups

International Journal of Clinical Practice

Volumn 65, Issue 4, 2011, Pages 436-445

  Bays, Harold E ^a   Shah, A ^b   Dong, Q ^b   McCrary Sisk, C ^b   Maccubbin, D ^b  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FLUSHING; GENDER; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

ADULT; AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; INDOLES; MALE; MIDDLE AGED; NIACIN; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 79952745060     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02620.x     Document Type: Article

References (22)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol In adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
2. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-10.
3. Gotto AM. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J 2002; 144: S33-42.
4. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins - an idea whose time for testing is coming, Part I. Circulation 2001; 104: 2376-83. (Pubitemid 33049524)
5. Knopp RH, Ginsberg J, Albers JJ et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985; 34: 642-50. (Pubitemid 15036921)
6. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth J Med 2004; 62: 229-34. (Pubitemid 39193956)
7. Illingworth DR, Stein EA, Mitchel YB et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Arch Intern Med 1994; 154: 1586-95. (Pubitemid 24242345)
8. Mills E, Prousky J, Raskin G et al. The safety of over-the-counter niacin. A randomized placebo-controlled trial. BMC Clin Pharmacol 2003; 3: 4-11.
9. Cheng K, Wu TJ, Wu KK et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A 2006; 103: 6682-7.
10. Sturino CF, O'Neill G, Lachance N et al. Discovery of a potent and selective prostaglandin D(2) receptor antagonist, [(3R)-4-(4-Chloro-benzyl)-7- fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem 2007; 50: 794-806.
11. Paolini JF, Mitchel YB, Reyes R et al. Effects of laropiprant on nicotinic acid-induced flushing in dyslipidemic patients. Am J Cardiol 2008; 101: 625-30.
12. Maccubbin D, Bays HE, Olsson AG et al. Lipid-modifying efficacy and tolerability of extendedrelease niacin/laropiprant in patients with primary hypercholesteroaemia or mixed dyslipidaemia. Int J Clin Pract 2008; 62: 1959-70.
13. Gleim G, Ballantyne CM, Liu N et al. Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br J Cardiol 2009; 16: 90-7.
14. Maccubbin D, Koren MJ, Davidson M et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009; 104: 74-81.
15. MacLean A, McKenney JM, Scott R et al. Efficacy and safety of extended release niacin/laropiprant in patients with type 2 diabetes mellitus. Br J Cardiol 2011. In press.
16. Heart Disease, and Stroke Statistics - 2005 Update. Dallas, Texas: American Heart Association, 2005. http://www.americanheart.org/presenter.jhtml? identifier=1928 Accessed: 15 October 2010
17. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
18. Pekkanen J, Linn S, Heiss G et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1700-7. (Pubitemid 20231527)
19. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34. (Pubitemid 28350165)
20. Bays HE, Shah A, Lin J et al. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. J Clin Lipidol 2010; 4: 515-21.
21. Niaspan [(Niacin Extended-Release Tablets) US Prescribing Information] Abbott Park, IL: Abbott Pharmaceuticals; 2005. Available at: http://www.rxabbott.com/U1-home.cfm
22. Bays HE, Ballantyne C. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr Opin Lipidol 2009; 20: 467-76.